Participation in the 4 weeks preceding inclusion or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure. 
Receipt of any vaccine in the 4 weeks preceding each trial vaccination or planned receipt of any vaccine in the 4 weeks following each trial vaccination, except for: 
(i) influenza vaccination, which may be received at least 2 weeks before study vaccines. 
(ii) measles (M) or measles, mumps, rubella (MMR) routine vaccination, which can be administered concomitantly with the first dose of study vaccine as per routine immunization schedule 
(iii) for subjects enrolled at Indian sites: oral poliomyelitis vaccine (OPV) received during National Immunization Days (NIDs) and supplementary immunization activity days (SIADs) 
Previous vaccination against meningococcal disease with either the study vaccine or another meningococcal vaccine 
Receipt of immune globulins, blood or blood-derived products in the past 3 months 
Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) 
History of meningococcal diseases, confirmed either clinically, serologically, or microbiologically 
At high risk, in the opinion of the Investigator, for meningococcal disease during the trial 
Known or suspected systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances 
Known thrombocytopenia, contraindicating intramuscular vaccination 
Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination 
In an emergency setting, or hospitalized involuntarily 
Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion 
For subjects enrolled at Indian sites: Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0°C). 
For subjects enrolled at Russian sites: Acute disease of any severity on the day of vaccination or febrile illness (axillary temperature ≥ 37.0°C). 
A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided. 
Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw 
Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study 
Personal history of Guillain-Barré Syndrome.       
    

NCT01890759_exc_T1
Temporal
4 weeks preceding inclusion
NCT01890759_exc_T2
Reference_point
inclusion
NCT01890759_exc_T3
Observation
planned participation
NCT01890759_exc_T6
Drug
vaccine
NCT01890759_exc_T7
Temporal
in the 4 weeks preceding each trial vaccination
NCT01890759_exc_T8
Reference_point
each trial vaccination
NCT01890759_exc_T9
Temporal
in the 4 weeks following each trial vaccination
NCT01890759_exc_T10
Reference_point
each trial vaccination
NCT01890759_exc_T11
Observation
planned receipt
NCT01890759_exc_T12
Drug
vaccine
NCT01890759_exc_T14
Drug
influenza vaccination
NCT01890759_exc_T15
Temporal
at least 2 weeks before study vaccines
NCT01890759_exc_T16
Reference_point
study vaccines
NCT01890759_exc_T17
Negation
except for
NCT01890759_exc_T18
Procedure
measles (M) vaccination
NCT01890759_exc_T19
Procedure
measles, mumps, rubella (MMR) vaccination
NCT01890759_exc_T20
Temporal
concomitantly with the first dose of study vaccine
NCT01890759_exc_T21
Reference_point
the first dose of study vaccine
NCT01890759_exc_T22
Scope
measles (M) or measles, mumps, rubella (MMR) routine vaccination
NCT01890759_exc_T23
Visit
Indian sites
NCT01890759_exc_T24
Drug
oral poliomyelitis vaccine (OPV)
NCT01890759_exc_T25
Temporal
during National Immunization Days (NIDs)
NCT01890759_exc_T26
Reference_point
National Immunization Days (NIDs)
NCT01890759_exc_T27
Temporal
during supplementary immunization activity days (SIADs)
NCT01890759_exc_T28
Reference_point
supplementary immunization activity days (SIADs)
NCT01890759_exc_T29
Scope
during National Immunization Days (NIDs) and supplementary immunization activity days (SIADs)
NCT01890759_exc_T30
Procedure
vaccination against meningococcal disease
NCT01890759_exc_T31
Drug
study vaccine
NCT01890759_exc_T32
Drug
another meningococcal vaccine
NCT01890759_exc_T33
Drug
immune globulins
NCT01890759_exc_T34
Drug
blood
NCT01890759_exc_T35
Drug
blood-derived products
NCT01890759_exc_T36
Temporal
in the past 3 months
NCT01890759_exc_T37
Scope
immune globulins, blood or blood-derived products
NCT01890759_exc_T38
Condition
acquired immunodeficiency
NCT01890759_exc_T39
Condition
congenital immunodeficiency
NCT01890759_exc_T40
Procedure
immunosuppressive therapy
NCT01890759_exc_T41
Procedure
anti-cancer chemotherapy
NCT01890759_exc_T42
Procedure
radiation therapy
NCT01890759_exc_T43
Temporal
within the preceding 6 months
NCT01890759_exc_T44
Procedure
systemic corticosteroid therapy
NCT01890759_exc_T45
Multiplier
long-term
NCT01890759_exc_T46
Drug
prednisone
NCT01890759_exc_T47
Temporal
for more than 2 consecutive weeks
NCT01890759_exc_T48
Temporal
within the past 3 months
NCT01890759_exc_T49
Scope
anti-cancer chemotherapy or radiation therapy
NCT01890759_exc_T50
Observation
suspected
NCT01890759_exc_T51
Observation
Known
NCT01890759_exc_T52
Scope
Known or suspected
NCT01890759_exc_T53
Scope
congenital or acquired immunodeficiency
NCT01890759_exc_T54
Condition
meningococcal diseases
NCT01890759_exc_T55
Procedure
serologically
NCT01890759_exc_T56
Procedure
microbiologically
NCT01890759_exc_T57
Value
confirmed
NCT01890759_exc_T60
Condition
systemic hypersensitivity
NCT01890759_exc_T61
Drug
vaccine components
NCT01890759_exc_T62
Observation
history
NCT01890759_exc_T63
Condition
life-threatening reaction
NCT01890759_exc_T64
Drug
vaccine
NCT01890759_exc_T65
Drug
vaccine
NCT01890759_exc_T66
Qualifier
used in the trial
NCT01890759_exc_T69
Condition
thrombocytopenia
NCT01890759_exc_T70
Condition
contraindicating
NCT01890759_exc_T71
Procedure
intramuscular vaccination
NCT01890759_exc_T72
Condition
Bleeding disorder
NCT01890759_exc_T73
Drug
anticoagulants
NCT01890759_exc_T74
Temporal
in the 3 weeks preceding inclusion
NCT01890759_exc_T75
Reference_point
inclusion
NCT01890759_exc_T76
Condition
contraindicating
NCT01890759_exc_T77
Procedure
intramuscular vaccination
NCT01890759_exc_T78
Scope
Bleeding disorder, or receipt of anticoagulants
NCT01890759_exc_T79
Visit
emergency setting
NCT01890759_exc_T80
Procedure
hospitalized
NCT01890759_exc_T81
Qualifier
involuntarily
NCT01890759_exc_T82
Condition
hospitalized involuntarily
NCT01890759_exc_T84
Visit
Indian sites
NCT01890759_exc_T85
Qualifier
Moderate
NCT01890759_exc_T86
Qualifier
severe
NCT01890759_exc_T87
Condition
acute illness
NCT01890759_exc_T88
Condition
acute infection
NCT01890759_exc_T90
Temporal
on the day of vaccination
NCT01890759_exc_T91
Reference_point
the day of vaccination
NCT01890759_exc_T92
Condition
febrile illness
NCT01890759_exc_T93
Measurement
temperature
NCT01890759_exc_T94
Value
≥ 38.0°C
NCT01890759_exc_T95
Scope
acute illness/infection
NCT01890759_exc_T96
Scope
Moderate or severe
NCT01890759_exc_T97
Scope
Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0°C)
NCT01890759_exc_T98
Visit
Russian sites
NCT01890759_exc_T99
Condition
Acute disease
NCT01890759_exc_T100
Temporal
on the day of vaccination
NCT01890759_exc_T101
Reference_point
the day of vaccination
NCT01890759_exc_T102
Condition
febrile illness
NCT01890759_exc_T103
Measurement
axillary temperature
NCT01890759_exc_T104
Value
≥ 37.0°C
NCT01890759_exc_T105
Scope
Acute disease of any severity on the day of vaccination or febrile illness (axillary temperature ≥ 37.0°C)
NCT01890759_exc_T108
Drug
antibiotic therapy
NCT01890759_exc_T109
Qualifier
injectable
NCT01890759_exc_T110
Qualifier
oral
NCT01890759_exc_T111
Scope
oral or injectable
NCT01890759_exc_T112
Temporal
within 72 hours prior to the first blood draw
NCT01890759_exc_T113
Reference_point
the first blood draw
NCT01890759_exc_T115
Condition
Guillain-Barré Syndrome
NCT01890759_exc_T116
Observation
history